NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support 24 Feb 2016 (#6)

[Click on blue hyperlink for further information]

*The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.*

*Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard (eugeneb@sun.ac.za), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.***

Important notices

- **Notice of Intent to Publish a Funding Opportunity Announcement for Alzheimer's Disease Clinical Trials Consortium (U24) (NOT-AG-16-016)**
- **Notice of Intent to Publish a Funding Opportunity Announcement for Bioengineering Research Grants (BRG) (R01) (NOT-EB-16-001)**
- **Notice of Intent to Publish a Funding Opportunity Announcement for NHLBI's Precision Interventions for Severe and Exacerbation-Prone (PrecISE) Asthma Network (U10) (NOT-HL-16-300)**
- **NHLBI Announces High Priority Interest in Zika Virus-related Blood Supply Safety and Transfusion Research (NOT-HL-16-307)**
- **AHRQ Announces New Policy for Public Access to AHRQ-Funded Scientific Publication (NOT-HS-16-008)**

1. Multidisciplinary Research in Vulvodynia

Letter of Intent due date: Usually 30 days prior to the application due date **Hyperlink:** (PA-16-101) (PA-16-100) (PA-16-102) **Type:** **R03** **R21** **R01**

Application Due Date: Standard dates Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to indicate a continued interest in the topic area of vulvodynia or chronic vulvar pain of unknown etiology as an integral area of branch research. This announcement is intended to encourage new research applications in the exploration of etiology, prevention, diagnosis, and therapeutics in the field of vulvodynia. Applications utilizing multidisciplinary approaches and interdisciplinary investigative teams are of particular interest to advance this research agenda.

Budget: **R03:** The combined budget for direct costs for the two year project period may not exceed $100,000. No more than $50,000 in direct costs may be requested in any single year. **R21:** The combined budget for direct costs for the two year project period may not exceed $275,000.No more than $200,000 may be requested in any single year. **R01:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The project period is limited to 5 years.

2. Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer

Letter of Intent due date: 6 weeks prior to the Application Due Date(s) **Hyperlink:** (PAR-16-105) **Type:** **U01**

Application Due Date: May 31, 2016; November 30, 2016; May 30, 2017; November 30, 2017; May 30, 2018; November 30, 2018. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology. The projects supported by this FOA will establish and collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program. The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.

Budget: Budgets are limited to $400,000 Direct Costs per year. Application budgets should reflect the actual needs of the proposed project. The maximum project period is 5 years. The scope of the proposed project should determine the project period

3. Rapid Assessment of Zika Virus (ZIKV) Complications

Letter of Intent due date: N/A **Hyperlink:** (PAR-16-106) **Type:** **R21**

Application Due Date: Applications will be accepted on a rolling basis, beginning on April 20, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited (rapid) funding mechanism for research on Zika virus (ZIKV) and its complications. ZIKV is a single-stranded RNA virus of the Flaviviridae family. It is transmitted to humans primarily through the bites of infected Aedes mosquitos, though both perinatal/in utero and sexual transmission have been reported. Initially discovered in 1947, it has been reported in the Americas since 2014, with a major outbreak in Brazil starting in 2015. Disease is seen in about 20% of infected people and is usually self-limited. However, a possible association between ZIKV infection in pregnant women and severe microcephaly in their babies has been very concerning and prompted the World Health Organization to declare this potential complication a public health emergency. Additionally the virus has been found in blood, fueling growing concerns about the risk of transfusion-transmission with particular concern over severe outcomes in at risk transfusion recipient populations such as women who are pregnant.

Budget: Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year. The scope of the project should determine the project period. The maximum period is 2 years

National Institutes of Health
Turning Discovery Into Health

Brief definitions of some NIH grant mechanisms: *comprehensive list of extramural grant and cooperative agreement activity codes*

D71 - International Research Training Planning Grant: To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

D43 - International Research Training Grants: To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

DP1 – NIH Director's Pioneer Award (NDPA): To support individuals who have the potential to make extraordinary contributions to medical research. The NIH Director's Pioneer Award is not renewable.

DP3 – Institutional Training and Director Program Projects -Type 1 Diabetes Targeted Research Award: To support research tackling major challenges in type 1 diabetes and promoting new approaches to these challenges by scientific teams.

P20 – Research Program Projects and Centers -Exploratory Grant: To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <$50,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

UH2/UH3 – NIH Phase Innovation Awards Cooperative Agreement: To support the development of new research activities in categorical program areas. (Support generally is restricted in level of support and in time.) The UH3 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the UH2 mechanism. Although only UH2 awardees are generally eligible to apply for UH3 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under UH2.

U2R – International Research Training Cooperative Agreements: Cooperative agreement mechanism for D43 to support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

U19 - Research Program-Cooperative Agreements: supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

Glossary of selected acronyms:

FOA	Funding Opportunity Announcement
PA	Program Announcements *(click on "PA" to search for further funding opportunities)*
RFA	Request for Applications *(click on "RFA" to search for further funding opportunities)*

Complete Glossary and acronym list of NIH Terms